Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥55 years of age remains to be determined. The myeloablative reduced-toxicity 4-day regimen IV busulfan (Bu) (130 mg/m(2))-IV fludarabine (Flu) (40 mg/m(2)) is associated with low morbidi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Alatrash, Gheath, de Lima, Marcos, Hamerschlak, Nelson, Pelosini, Matteo, Wang, Xuemei, Xiao, Lianchun, Kerbauy, Fabio, Chiattone, Alexandre, Rondon, Gabriela, Qazilbash, Muzaffar H., Giralt, Sergio A., de Padua Silva, Leandro, Hosing, Chitra, Kebriaei, Partow, Zhang, Weiqing, Nieto, Yago, Saliba, Rima M., Champlin, Richard E., Andersson, Borje S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4261630/
https://ncbi.nlm.nih.gov/pubmed/21338705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2011.02.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados